patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_853157 | REC_0013701 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 7.6 | 73 | female | 3 | 10 | 4.4 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.492890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715076 | REC_0013702 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 12.4 | 62 | male | 1 | 16 | 5.5 | 2 | sotorasib 960 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:36:00.493209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421353 | REC_0013703 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.5 | 52 | male | 0 | 19 | 3.2 | 5 | osimertinib 80 mg daily | 8.5 | true | MSS | 2026-03-15T05:36:00.493674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730237 | REC_0013704 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.8 | 77 | female | 1 | 15 | 7.6 | 3 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.494005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347503 | REC_0013705 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 35 | 12.6 | 67 | female | 0 | 16 | 4.6 | 4 | osimertinib 80 mg daily | 16 | false | MSS | 2026-03-15T05:36:00.494330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723226 | REC_0013706 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 17 | 73 | female | 2 | 3 | 4.6 | 5 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:36:00.494681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332079 | REC_0013707 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 8.2 | 58 | male | 1 | 7 | 3.9 | 0 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:36:00.495051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324241 | REC_0013708 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 15.8 | 54 | male | 0 | 12 | 4.1 | 0 | alectinib 600 mg BID | 40.9 | false | MSS | 2026-03-15T05:36:00.495410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219942 | REC_0013709 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.4 | 77 | female | 3 | 44 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 26 | true | MSS | 2026-03-15T05:36:00.495757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369480 | REC_0013710 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 11.9 | 73 | female | 1 | 17 | 5.3 | 2 | osimertinib 80 mg daily | 21.7 | false | MSI-H | 2026-03-15T05:36:00.496171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373713 | REC_0013711 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.2 | 56 | male | 0 | 11 | 8 | 1 | entrectinib 600 mg daily | 22.1 | true | MSI-H | 2026-03-15T05:36:00.496590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658350 | REC_0013712 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 15.7 | 81 | female | 2 | 25 | 5.1 | 6 | osimertinib 80 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:36:00.497009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130285 | REC_0013713 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 4.3 | 80 | female | 2 | 4 | 4.1 | 4 | osimertinib 80 mg daily | 9.4 | true | MSS | 2026-03-15T05:36:00.497353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231148 | REC_0013714 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12 | 66 | female | 0 | 10 | 3.3 | 4 | entrectinib 600 mg daily | 9.5 | false | MSS | 2026-03-15T05:36:00.497705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438878 | REC_0013715 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12 | 70 | female | 2 | 12 | 4.3 | 1 | sotorasib 960 mg daily | 24.6 | true | MSI-H | 2026-03-15T05:36:00.498112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508303 | REC_0013716 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11 | 53 | male | 0 | 12 | 5.4 | 9 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:36:00.498649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425843 | REC_0013717 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 33 | 12.6 | 66 | female | 1 | 17 | 4.6 | 0 | entrectinib 600 mg daily | 49.6 | true | MSI-H | 2026-03-15T05:36:00.499036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261487 | REC_0013718 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 10.5 | 58 | female | 0 | 40 | 6.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSI-H | 2026-03-15T05:36:00.499390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561695 | REC_0013719 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.2 | 58 | female | 0 | 6 | 4.2 | 2 | alectinib 600 mg BID | 15.1 | true | MSI-H | 2026-03-15T05:36:00.499756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268931 | REC_0013720 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 16.6 | 84 | male | 1 | 9 | 4.9 | 0 | entrectinib 600 mg daily | 47 | false | MSS | 2026-03-15T05:36:00.502158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938836 | REC_0013721 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.4 | 62 | male | 0 | 14 | 7 | 6 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:36:00.502675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344111 | REC_0013722 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9.7 | 57 | female | 1 | 2 | 6.3 | 4 | osimertinib 80 mg daily | 7.9 | true | MSS | 2026-03-15T05:36:00.503041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570088 | REC_0013723 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.4 | 64 | male | 1 | 17 | 2 | 5 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:00.503373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787462 | REC_0013724 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5 | 85 | female | 1 | 62 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 14 | false | MSS | 2026-03-15T05:36:00.503694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969905 | REC_0013725 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 15 | 65 | female | 1 | 28 | 5.8 | 1 | osimertinib 80 mg daily | 16.2 | true | MSS | 2026-03-15T05:36:00.504041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935544 | REC_0013726 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 16.7 | 56 | female | 0 | 19 | 7.3 | 2 | entrectinib 600 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:00.504508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696258 | REC_0013727 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.8 | 74 | female | 1 | 17 | 6.2 | 5 | entrectinib 600 mg daily | 17.6 | false | MSS | 2026-03-15T05:36:00.504901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622256 | REC_0013728 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 9.2 | 71 | female | 1 | 20 | 6.2 | 2 | sotorasib 960 mg daily | 21.1 | false | MSS | 2026-03-15T05:36:00.505301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780328 | REC_0013729 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.4 | 55 | male | 0 | 13 | 6.2 | 5 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:36:00.505809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287937 | REC_0013730 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 6.7 | 77 | female | 2 | 19 | 4.6 | 4 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:36:00.506199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563761 | REC_0013731 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.4 | 69 | male | 1 | 33 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.9 | false | MSS | 2026-03-15T05:36:00.506547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468770 | REC_0013732 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 6.5 | 69 | female | 1 | 11 | 6.3 | 3 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:36:00.506865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806824 | REC_0013733 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.9 | 41 | male | 0 | 4 | 3.8 | 7 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:36:00.507150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941493 | REC_0013734 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 16.4 | 69 | female | 0 | 12 | 4.7 | 7 | entrectinib 600 mg daily | 16.7 | true | MSS | 2026-03-15T05:36:00.507457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955207 | REC_0013735 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 17.4 | 79 | female | 1 | 11 | 6.1 | 3 | alectinib 600 mg BID | 9.7 | false | MSS | 2026-03-15T05:36:00.507757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205197 | REC_0013736 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.6 | 57 | male | 0 | 17 | 6.3 | 7 | alectinib 600 mg BID | 15.9 | false | MSI-H | 2026-03-15T05:36:00.508131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300145 | REC_0013737 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 8.2 | 64 | female | 0 | 49 | 6.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:36:00.508510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924790 | REC_0013738 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.5 | 76 | female | 2 | 14 | 4 | 6 | entrectinib 600 mg daily | 5.9 | true | MSS | 2026-03-15T05:36:00.508838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931293 | REC_0013739 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 12.9 | 65 | female | 1 | 9 | 4 | 4 | alectinib 600 mg BID | 17.5 | true | MSS | 2026-03-15T05:36:00.509150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763632 | REC_0013740 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 14.2 | 76 | female | 1 | 18 | 5.8 | 0 | osimertinib 80 mg daily | 44.5 | true | MSI-H | 2026-03-15T05:36:00.509460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892199 | REC_0013741 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.1 | 75 | female | 2 | 55 | 4.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:36:00.509796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371685 | REC_0013742 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.2 | 77 | female | 2 | 16 | 6.6 | 1 | entrectinib 600 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:36:00.510326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545770 | REC_0013743 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 13.1 | 74 | female | 1 | 16 | 5.7 | 3 | entrectinib 600 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:36:00.510698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442972 | REC_0013744 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.9 | 68 | male | 0 | 26 | 2.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:36:00.511013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635314 | REC_0013745 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 10.1 | 58 | female | 1 | 10 | 6.1 | 1 | alectinib 600 mg BID | 22.2 | true | MSS | 2026-03-15T05:36:00.511734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168618 | REC_0013746 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.2 | 62 | male | 0 | 21 | 5.2 | 2 | alectinib 600 mg BID | 20.5 | true | MSI-H | 2026-03-15T05:36:00.512160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630084 | REC_0013747 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 6.8 | 75 | female | 1 | 15 | 3 | 2 | pembrolizumab 200 mg q3w | 19.2 | false | MSS | 2026-03-15T05:36:00.512501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463489 | REC_0013748 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 10.1 | 69 | female | 0 | 16 | 6.8 | 6 | entrectinib 600 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:36:00.512830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790153 | REC_0013749 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.6 | 61 | male | 0 | 57 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.5 | false | MSS | 2026-03-15T05:36:00.513154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619368 | REC_0013750 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 19.3 | 71 | female | 2 | 7 | 7.2 | 5 | entrectinib 600 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:00.513499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656001 | REC_0013751 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.5 | 66 | female | 0 | 64 | 3.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:36:00.513814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743914 | REC_0013752 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 5.6 | 70 | male | 2 | 16 | 6 | 5 | entrectinib 600 mg daily | 7.6 | true | MSS | 2026-03-15T05:36:00.514122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983968 | REC_0013753 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 18.6 | 63 | female | 1 | 19 | 4 | 8 | osimertinib 80 mg daily | 6.5 | true | MSI-H | 2026-03-15T05:36:00.514445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724135 | REC_0013754 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 12.1 | 84 | female | 2 | 8 | 6.6 | 7 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:36:00.514766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900200 | REC_0013755 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.8 | 75 | female | 3 | 44 | 4.8 | 6 | pembrolizumab 200 mg q3w | 5.6 | false | MSS | 2026-03-15T05:36:00.515272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986060 | REC_0013756 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 7.8 | 73 | female | 2 | 7 | 4.8 | 1 | osimertinib 80 mg daily | 21 | false | MSS | 2026-03-15T05:36:00.515637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862005 | REC_0013757 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 9.2 | 77 | female | 1 | 19 | 4.7 | 2 | alectinib 600 mg BID | 20.3 | false | MSS | 2026-03-15T05:36:00.515963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778959 | REC_0013758 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.8 | 71 | female | 2 | 46 | 4.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.2 | false | MSS | 2026-03-15T05:36:00.516356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497968 | REC_0013759 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 17.4 | 72 | female | 0 | 10 | 6.4 | 6 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:36:00.516661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632056 | REC_0013760 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5.8 | 64 | female | 0 | 65 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.5 | false | MSS | 2026-03-15T05:36:00.516958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249790 | REC_0013761 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 6.4 | 74 | female | 2 | 31 | 4.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:36:00.517260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184071 | REC_0013762 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 17.1 | 60 | male | 0 | 10 | 6 | 0 | entrectinib 600 mg daily | 64.9 | true | MSI-H | 2026-03-15T05:36:00.517562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621808 | REC_0013763 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8.1 | 73 | female | 1 | 67 | 3.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.7 | true | MSS | 2026-03-15T05:36:00.517864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491445 | REC_0013764 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.7 | 58 | female | 0 | 11 | 6.3 | 5 | osimertinib 80 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:00.518192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509270 | REC_0013765 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 11.9 | 65 | male | 0 | 15 | 4.6 | 6 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:00.518517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879759 | REC_0013766 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 15 | 70 | female | 1 | 14 | 4.3 | 4 | pembrolizumab 200 mg q3w | 10.9 | true | MSS | 2026-03-15T05:36:00.518839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699791 | REC_0013767 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 4.6 | 78 | male | 0 | 53 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 25.5 | false | MSS | 2026-03-15T05:36:00.519164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690228 | REC_0013768 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.3 | 68 | female | 0 | 12 | 4.9 | 5 | pembrolizumab 200 mg q3w | 18.2 | false | MSS | 2026-03-15T05:36:00.519663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285426 | REC_0013769 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 14.9 | 79 | female | 2 | 19 | 6 | 5 | alectinib 600 mg BID | 11.4 | true | MSI-H | 2026-03-15T05:36:00.520068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876943 | REC_0013770 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.8 | 59 | female | 1 | 3 | 5.7 | 6 | sotorasib 960 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:36:00.520468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124819 | REC_0013771 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 10.1 | 69 | female | 0 | 17 | 3.4 | 2 | entrectinib 600 mg daily | 15.6 | true | MSS | 2026-03-15T05:36:00.520823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343329 | REC_0013772 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.3 | 70 | female | 2 | 6 | 3.9 | 6 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:36:00.521165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304082 | REC_0013773 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 14 | 3.9 | 84 | female | 3 | 17 | 6.2 | 0 | sotorasib 960 mg daily | 45.1 | true | MSS | 2026-03-15T05:36:00.521470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531321 | REC_0013774 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 9.7 | 77 | female | 1 | 8 | 7.1 | 5 | alectinib 600 mg BID | 11.4 | true | MSS | 2026-03-15T05:36:00.521790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882253 | REC_0013775 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 33 | 6.8 | 68 | female | 0 | 34 | 4.8 | 2 | pembrolizumab 200 mg q3w | 19.9 | false | MSS | 2026-03-15T05:36:00.522138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989318 | REC_0013776 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.9 | 75 | female | 2 | 31 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.8 | true | MSS | 2026-03-15T05:36:00.522477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963642 | REC_0013777 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.7 | 60 | female | 0 | 0 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:36:00.522822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695199 | REC_0013778 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 5.9 | 83 | female | 2 | 15 | 6.3 | 2 | pembrolizumab 200 mg q3w | 20.5 | true | MSS | 2026-03-15T05:36:00.523139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530544 | REC_0013779 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 18.7 | 90 | male | 3 | 16 | 9.4 | 7 | entrectinib 600 mg daily | 6.7 | false | MSS | 2026-03-15T05:36:00.523451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795727 | REC_0013780 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 19.7 | 77 | male | 2 | 19 | 4.8 | 4 | sotorasib 960 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:00.523781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589190 | REC_0013781 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 18.8 | 56 | female | 1 | 16 | 6.5 | 1 | sotorasib 960 mg daily | 32.9 | false | MSI-H | 2026-03-15T05:36:00.524404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753654 | REC_0013782 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.8 | 65 | female | 0 | 9 | 5 | 2 | entrectinib 600 mg daily | 24.2 | false | MSI-H | 2026-03-15T05:36:00.524765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648707 | REC_0013783 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 10.5 | 70 | female | 2 | 12 | 4.7 | 5 | alectinib 600 mg BID | 13 | true | MSI-H | 2026-03-15T05:36:00.525082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105145 | REC_0013784 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10.7 | 68 | female | 0 | 10 | 2.2 | 1 | alectinib 600 mg BID | 17 | true | MSI-H | 2026-03-15T05:36:00.525379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833474 | REC_0013785 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 17.7 | 66 | female | 0 | 13 | 4.5 | 7 | alectinib 600 mg BID | 7.7 | true | MSI-H | 2026-03-15T05:36:00.525663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584196 | REC_0013786 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.8 | 60 | male | 1 | 14 | 6.3 | 1 | osimertinib 80 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:36:00.525957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482234 | REC_0013787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 2.1 | 76 | male | 3 | 10 | 4.1 | 6 | entrectinib 600 mg daily | 8.7 | true | MSS | 2026-03-15T05:36:00.526268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610741 | REC_0013788 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.1 | 58 | male | 1 | 13 | 6.2 | 2 | osimertinib 80 mg daily | 27.4 | false | MSS | 2026-03-15T05:36:00.526575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868500 | REC_0013789 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 14.5 | 62 | female | 1 | 15 | 6.2 | 9 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:36:00.526890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349711 | REC_0013790 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 37 | 7.5 | 78 | female | 1 | 15 | 5.1 | 6 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:36:00.527185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189917 | REC_0013791 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 8.6 | 68 | female | 1 | 15 | 2.3 | 6 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:36:00.527474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148410 | REC_0013792 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 8.2 | 66 | male | 1 | 44 | 4 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.5 | false | MSS | 2026-03-15T05:36:00.527776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674000 | REC_0013793 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 13.7 | 85 | female | 2 | 10 | 4.9 | 0 | alectinib 600 mg BID | 16.8 | true | MSS | 2026-03-15T05:36:00.528067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315566 | REC_0013794 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 5.6 | 57 | male | 0 | 12 | 6 | 6 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:36:00.528605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703309 | REC_0013795 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14 | 63 | male | 0 | 2 | 4.6 | 1 | osimertinib 80 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:36:00.528951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181937 | REC_0013796 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10.5 | 73 | female | 2 | 22 | 6.7 | 2 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:00.529264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403772 | REC_0013797 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 16.1 | 67 | female | 1 | 21 | 5.5 | 6 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:36:00.529573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762182 | REC_0013798 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 3.3 | 74 | female | 1 | 48 | 4.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 22.6 | false | MSS | 2026-03-15T05:36:00.529873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696268 | REC_0013799 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 10.9 | 78 | male | 2 | 15 | 6.5 | 0 | sotorasib 960 mg daily | 24.2 | true | MSS | 2026-03-15T05:36:00.530193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612620 | REC_0013800 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 21.6 | 60 | female | 0 | 12 | 4.3 | 7 | osimertinib 80 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:36:00.530493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.